Pregabalin Capsule
Product Images NDC 62332-121

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 62332-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-equation.jpg (Pregabalin Equation)

A formula showing how to calculate creatinine clearance (CLCr) using age, weight, serum creatinine, and a factor for female patients. The formula is presented as an equation involving these variables.*

FDA Label Image

Structure (Pregabalin Structure)

Chemical structure diagram of the active ingredient pregabalin, showing its molecular arrangement with an amino group, carboxyl group, and hydrocarbon chains.*

FDA Label Image

Figure 1 (Pregabalin Figure1)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin capsules at doses of 25 mg, 100 mg, and 200 mg taken three times a day, along with placebo. The graph shows separate lines for each dose and placebo, illustrating differences in patient pain improvement percentages across the range.*

FDA Label Image

Figure 2 (Pregabalin Figure2)

A line graph comparing percent improvement in pain from baseline (x-axis) to percent of patients improved (y-axis) between Pregabalin 100 mg three times a day and placebo. The chart displays two lines indicating higher patient improvement percentages for Pregabalin compared to placebo across all levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig3)

A line graph plotting percent of patients improved against percent improvement in pain from baseline, comparing Pregabalin dosages (75 mg, 150 mg, 300 mg, each taken three times a day) with placebo. The horizontal axis shows percent improvement in pain from baseline, and the vertical axis shows the percent of patients improved. Different line styles distinguish each treatment and placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig4)

This line graph compares the percent of patients improved relative to the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows the percent of patients improved, while the x-axis represents the percent improvement in pain from baseline. The graph includes three trend lines illustrating patient response differences among the three groups.*

FDA Label Image

Figure 5 (Pregabalin Fig5)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The graph includes vertical markers at specific improvement percentages between 30% and 50%.*

FDA Label Image

Figure 6 (Pregabalin Fig6)

A bar chart comparing responder rates (%) in two clinical studies, Study E1 and Study E3, of Pregabalin at various dosages (mg/day) versus placebo. The x-axis shows dosage groups including placebo and Pregabalin doses with administration frequency (BID or TID). The y-axis shows responder rate percentages, highlighting higher response rates with increasing Pregabalin doses compared to placebo, with statistical significance noted.*

FDA Label Image

Figure 7 (Pregabalin Fig7)

A line graph showing seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin across four different studies (E1 BID, E2 TID, E3 BID, E3 TID). The graph depicts increasing seizure reduction with dosage, including statistical significance (p-values) at various doses.*

FDA Label Image

Pregabalin-fig8.jpg (Pregabalin Fig8)

A bar graph showing responder rates (%) on the vertical axis and treatment groups on the horizontal axis. It compares placebo with two doses of Pregabalin (2.5 mg/kg/day and 10 mg/kg/day). Percentages are 22.6% (placebo), 29.1% (2.5 mg/kg/day), and 40.6% (10 mg/kg/day). Sample sizes are 93, 103, and 96 respectively.*

FDA Label Image

Figure 9 (Pregabalin Fig9)

A line graph illustrating percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin daily doses of 300 mg, 450 mg, and 600 mg with placebo, using different line styles for each treatment group across the pain improvement range from 0 to 100 percent.*

FDA Label Image

Figure 10 (Pregabalin Fig10)

A survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (likely 'loss to relapse'), ranging from 0% to 100%. The x-axis represents days from 0 to 180. Two lines plotted: a solid line for Pregabalin and a dashed line for placebo, with Pregabalin showing higher percentages of subjects without LTR throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over a range of percent improvement from baseline to Week 12 using the BOCF method. Two lines are shown: one for Pregabalin and one for Placebo. The x-axis represents percent improvement from 0% to 100%, and the y-axis shows the percentage of subjects improved from 0% to 100%. The graph illustrates a higher percentage of subjects improving with Pregabalin compared to Placebo across the improvement spectrum.*

FDA Label Image

Figure 12 (Pregabalin Fig12)

A line graph comparing the percent of subjects improved over time between Pregabalin and placebo from baseline to Week 16, using the BOCF method. The x-axis shows percent improved, and the y-axis shows the percent of subjects improved, with Pregabalin represented by a solid line and placebo by a dashed line.*

FDA Label Image

Pregabalin-25-mg (Pregabalin 25 mg)

Pregabalin Capsules 25 mg oral dosage form packaging label from Alembic Pharmaceuticals Inc. with NDC 62332-119-30. The label includes storage instructions (store at 25°C with excursions permitted), prescription only use, manufacturer details (Alembic Pharmaceuticals Limited, Gujarat, India), the capsule count (30 capsules), and a barcode. The design features the Alembic logo and highlights the 25 mg strength in red.*

FDA Label Image

Pregabalin-50-mg (Pregabalin 50 mg)

Label for Pregabalin Capsules 50 mg by Alembic Pharmaceuticals Inc. The label includes dosage form as capsules, a quantity of 30 capsules per container, and note that each capsule contains 50 mg of pregabalin USP. It features storage information at controlled room temperature and a reference to accompanying prescribing information. The label includes the NDC 62332-120-30 and instructions for pharmacists to dispense the medication guide separately.*

FDA Label Image

Pregabalin-75-mg (Pregabalin 75 mg)

Label of Pregabalin Capsules 75 mg by Alembic Pharmaceuticals Inc., showing NDC 62332-121-30. The label indicates the product contains 75 mg pregabalin per capsule, with storage instructions at 25°C, and includes manufacturer and distributor details. The package contains 30 capsules and is marked Rx only.*

FDA Label Image

Pregabalin-100-mg (Pregabalin 100 mg)

Pregabalin Capsules 100 mg oral capsules label from Alembic Pharmaceuticals Inc. The label includes dosage and storage instructions, manufacturer and distributor details, NDC 62332-122-30, quantity of 30 capsules per container, and a barcode. It specifies that the product is prescription only and advises pharmacists to dispense the medication guide separately.*

FDA Label Image

Pregabalin-150-mg (Pregabalin 150 mg)

Label for Pregabalin Capsules 150 mg by Alembic Pharmaceuticals Inc. The label includes dosage information, storage instructions, manufacturer details (Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA), and a 30-capsule package size. It features a barcode, NDC 62332-123-30, and directions for pharmacists to dispense the Medication Guide. The label also indicates the product is Rx only.*

FDA Label Image

Pregabalin-200-mg (Pregabalin 200 mg)

Label for Pregabalin Capsules 200 mg by Alembic Pharmaceuticals Inc. The label states each capsule contains 200 mg pregabalin USP. The package contains 30 capsules and is for oral use. Storage instructions specify 25°C with permitted excursions. The label includes NDC 62332-124-30 and cautions dispensing in tight containers. Manufacturer information is provided for Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA.*

FDA Label Image

Pregabalin-225-mg (Pregabalin 225 mg)

Pregabalin Capsules 225 mg oral dosage form carton label from Alembic Pharmaceuticals Inc. The label indicates 30 capsules per container with storage instructions at 25°C (77°F) and excursions permitted between 15-30°C (59-86°F). It includes manufacturer details, a barcode, and instructions for pharmacists to dispense a separate Medication Guide. The label also lists the NDC 62332-125-30 and warns that the coding area is not to be printed.*

FDA Label Image

Pregabalin-300-mg (Pregabalin 300 mg)

Pregabalin Capsules 300 mg oral capsules packaging label from Alembic Pharmaceuticals Inc. The label states each capsule contains 300 mg pregabalin USP, with a quantity of 30 capsules. It includes storage instructions, manufacturing details from Alembic Pharmaceuticals Limited in India, and for Alembic Pharmaceuticals, Inc. in the USA. Contains directions for pharmacists and a barcode, NDC 62332-126-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.